These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29205493)

  • 1. Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy.
    Fournier Q; Serra JC; Handel I; Lawrence J
    J Vet Intern Med; 2018 Jan; 32(1):384-393. PubMed ID: 29205493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol.
    Simon D; Nolte I; Eberle N; Abbrederis N; Killich M; Hirschberger J
    J Vet Intern Med; 2006; 20(4):948-54. PubMed ID: 16955821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
    Wang SL; Lee JJ; Liao AT
    Vet J; 2015 Jul; 205(1):69-73. PubMed ID: 26004824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a 0.75 × 10
    Bisson JL; Fournier Q; Johnston E; Handel I; Bavcar S
    Vet Comp Oncol; 2020 Sep; 18(3):258-268. PubMed ID: 31600416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy.
    Scott SD; Chrischilles EA; Link BK; Delgado DJ; Fridman M; Stolshek BS
    J Manag Care Pharm; 2003; 9(2 Suppl):15-21. PubMed ID: 14613340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
    Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
    J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
    Lyman GH; Delgado DJ
    Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
    Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Sutheesophon J; Sutcharitchan P; Swasdikul D
    Leuk Lymphoma; 2000 Apr; 37(3-4):351-60. PubMed ID: 10752986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
    Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
    Wang SL; Lee JJ; Liao AT
    Can Vet J; 2016 Mar; 57(3):271-6. PubMed ID: 26933263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ventricular fractional shortening in 108 dogs with malignant lymphoma undergoing chemotherapy with a cyclic combination protocol including doxorubicin.
    Tater G; Eberle N; Hungerbuehler S; Joetzke A; Nolte I; Wess G; Betz D
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2012; 40(4):261-6. PubMed ID: 22911257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal and hematologic adverse events after administration of vincristine, cyclophosphamide, and doxorubicin in dogs with lymphoma that underwent a combination multidrug chemotherapy protocol.
    Tomiyasu H; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
    J Vet Med Sci; 2010 Nov; 72(11):1391-7. PubMed ID: 20543531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?
    Wang SL; Lee JJ; Liao AT
    Vet J; 2016 Jul; 213():87-9. PubMed ID: 27240922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutropenia associated with vincristine and L-asparaginase induction chemotherapy for canine lymphoma.
    Northrup NC; Rassnick KM; Snyder LA; Stone MS; Kristal O; Cotter SM; Moore AS
    J Vet Intern Med; 2002; 16(5):570-5. PubMed ID: 12322708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
    J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.
    Kikuchi M; Nakasone H; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Sakamoto K; Kawamura K; Ishihara Y; Sato M; Ashizawa M; Terasako-Saito K; Kimura S; Yamazaki R; Kako S; Kanda J; Nishida J; Sekiguchi N; Noto S; Kida M; Hangaishi A; Usuki K; Kanda Y
    J Chemother; 2015 Feb; 27(2):99-105. PubMed ID: 25314911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases.
    Sorenmo K; Overley B; Krick E; Ferrara T; LaBlanc A; Shofer F
    Vet Comp Oncol; 2010 Sep; 8(3):196-208. PubMed ID: 20691027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs.
    Rassnick KM; Bailey DB; Malone EK; Intile JL; Kiselow MA; Flory AB; Barlow LL; Balkman CE; Barnard SM; Waite AH
    Vet Comp Oncol; 2010 Dec; 8(4):243-53. PubMed ID: 21062406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.